Loading...
•
Apr 03, 2020
Danaher Q1 2020 Earnings Report
Danaher's first quarter performance was driven by positive results across all three reporting segments, with Cepheid, Radiometer, Pall, and ChemTreat businesses showing particular strength.
Key Takeaways
Danaher Corporation reported a 3.0% increase in revenues to $4.3 billion for the first quarter of 2020, with net earnings of $595.1 million, or $0.81 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $1.05, and core revenue growth was 4.5%. The company also closed its acquisition of the GE Biopharma business, now called Cytiva, on March 31.
Delivered 4.5% core revenue growth.
Closed acquisition of GE Biopharma business (Cytiva) on March 31.
Providing diagnostic testing capabilities and supporting the pursuit of new treatments and vaccines for COVID-19.
Well-positioned to navigate through the uncertain environment due to a strong portfolio, exceptional team, and disciplined execution.
Forward Guidance
For the second quarter of 2020, Danaher anticipates that non-GAAP core revenue growth including Cytiva will be in the range of approximately flat to down 10%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...